<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02552459</url>
  </required_header>
  <id_info>
    <org_study_id>FirstSunYetSen-jn2015</org_study_id>
    <nct_id>NCT02552459</nct_id>
  </id_info>
  <brief_title>Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery</brief_title>
  <official_title>Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine effect of combined medication of sufentanil and
      dexmedetomidine in patient controlled analgesia after neurosurgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sufentanil is a classical drug for postoperative analgesia. Dexmedetomidine is a commonly
      used α2-adrenergic receptor, and it helps provide sedation, analgesia and inhibition of
      sympathetic activation. The investigators propose to recruit 120 patients who is undergoing
      the arteriovenous malformation embolism operation in department of Neurosurgery. Patients
      will be randomly divided into 4 groups(control group, sufentanil and low dexmedetomidine dose
      group, sufentanil and middle dexmedetomidine dose group, sufentanil and high dexmedetomidine
      dose group), then the investigators select post-operative records to determine whether
      dexmedetomidine can take a positive role in neurosurgical analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain on the VAS scale</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure the VAS score at pre-operative day and post-operative 4h、8h、12h、24h、48h、72h。</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure(BP)(mmHg)</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure BP(mmHg),HR (/min),spO2(%), and breath(/min),on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate(HR) (/min)</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure BP(mmHg),HR (/min),spO2(%), and breath(/min),on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>spO2(%)</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure BP(mmHg),HR (/min),spO2(%), and breath(/min),on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>breath(/min)</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure BP(mmHg),HR (/min),spO2(%), and breath(/min),on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sedation level on ramsay sedation score</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure sedation level using ramsay sedation score on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vomit times</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure vomit times on pre-operative day and at measure sedation level using ramsay sedation score on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>nausea</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure whether nausea exists on pre-operative day and at measure sedation level using ramsay sedation score on pre-operative day and at post-operative 4h、8h、12h、24h、48h、72h</description>
  </secondary_outcome>
  <other_outcome>
    <measure>dose of rescue tramadol</measure>
    <time_frame>within the following 72 hours after surgery</time_frame>
    <description>measure the dose of tramadol using as rescue drug on post-operative 24h、48h、72h</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Arteriovenous Malformation</condition>
  <arm_group>
    <arm_group_label>sufentanil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sufentanil 150μg，intravenous administration during the following 72 hours after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil&amp;dexmedetomidine 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sufentanil 150μg，dexmedetomidine 0.05μg/kg/h，intravenous administration during the following 72 hours after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentani&amp;dexmedetomidine 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sufentanil 150μg，dexmedetomidine 0.1μg/kg/h，intravenous administration during the following 72 hours after operation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sufentanil&amp;dexmedetomidine 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>sufentanil 150μg，dexmedetomidine 0.15μg/kg/h ，intravenous administration during the following 72 hours after operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
    <description>sufentanil 150μg， intravenous administration during post-operative 72 hours.</description>
    <arm_group_label>sufentanil</arm_group_label>
    <arm_group_label>sufentanil&amp;dexmedetomidine 1</arm_group_label>
    <arm_group_label>sufentani&amp;dexmedetomidine 2</arm_group_label>
    <arm_group_label>sufentanil&amp;dexmedetomidine 3</arm_group_label>
    <other_name>Sufentanyl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 1</intervention_name>
    <description>dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation</description>
    <arm_group_label>sufentanil&amp;dexmedetomidine 1</arm_group_label>
    <other_name>Dex,Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 2</intervention_name>
    <description>dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation</description>
    <arm_group_label>sufentani&amp;dexmedetomidine 2</arm_group_label>
    <other_name>Dex,Dexmedetomidine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine 3</intervention_name>
    <description>dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.</description>
    <arm_group_label>sufentanil&amp;dexmedetomidine 3</arm_group_label>
    <other_name>Dex,Dexmedetomidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients undergoing venous malformation embolization operation through general
             anesthesia.

          2. aged 18-65 years old.

          3. operating time varies 1-4h,and extubation after the operation.

        Exclusion Criteria:

          1. long-term use of analgesics,sedatives or non steroidal anti-inflammatory drugs
             history.

          2. known for dexmedetomidine or other drugs allergy in this study.

          3. cannot communicate.

          4. preoperative systolic blood pressure &lt;90 mmHg, or the heart rate &lt;50/min.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiang Nan, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Sun Yat-sen Unniversity</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shao Xinxin, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Sun Yat-sen Unniversity</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liu Yi, master</last_name>
    <phone>13632391455</phone>
    <phone_ext>+86</phone_ext>
    <email>liuyisysu@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jiang nan, doctor</last_name>
    <phone>13725407606</phone>
    <phone_ext>+86</phone_ext>
    <email>jiangnanshen@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Sun Yetsen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Liu, Master</last_name>
      <phone>+86 13632391455</phone>
      <email>liuyisysu@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Nan Jiang, professor</last_name>
      <phone>+86 20 28823350</phone>
      <email>NJiang_sysu@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2015</study_first_posted>
  <last_update_submitted>October 16, 2016</last_update_submitted>
  <last_update_submitted_qc>October 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Xinxin Shao</investigator_full_name>
    <investigator_title>resident</investigator_title>
  </responsible_party>
  <keyword>dexmedetomidine</keyword>
  <keyword>patient controlled analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Hemangioma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Sufentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

